Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders

Julia Kim, Eric Plitman, Yusuke Iwata, Shinichiro Nakajima, Wanna Mar, Raihaan Patel, Sofia Chavez, Jun Ku Chung, Fernando Caravaggio, M. Mallar Chakravarty, Gary Remington, Philip Gerretsen, Ariel Graff-Guerrero

Research output: Contribution to journalArticle

Abstract

Widespread structrual abnormalities in subcortical brain regions have been identified in patients with schizophrenia. However, only a few studies have examined the neuroanatomical profiles of patients with treatment-resistant schizophrenia. The aim of this study was to compare differences in subcortical and hippocampal volumes between: (i) treatment-resistant patients who are non-responders to both first-line antipsychotics and clozapine (URS), (ii) treatment-resistant patients who are non-responders to first-line antipsychotics but are responders to clozapine (CLZ-Resp), (iii) responders to first-line antipsychotics (FL-Resp), and (iv) healthy controls. T1-weighted images of 103 participants (27 URS, 29 CLZ-Resp, 21 FL-Resp, and 26 healthy controls) were obtained. Group differences in striatal, thalamic, globus pallidus, amygdala, and hippocampus volumes were examined. Multiple regression analyses were performed to examine the associations between subcortical and hippocampal volumes and participant characteristics. The FL-Resp group showed larger striatal and globus pallidus volumes compared to the URS group and larger post-commissural putamen and globus pallidus volumes compared to healthy controls. The URS group showed smaller thalamic volume compared to healthy controls. There were no subcortical or hippocampal volume differences between the URS and CLZ-Resp groups. Differences in subcortical and hippocampal structural volumes were not related to symptom severity or chlorpromazine antipsychotic dose equivalents. Our findings suggest different structural volume alterations in subcortical brain regions between treatment-resistant schizophrenia and responders to first-line antipsychotics. Whether subcortical structure compromise is a distinct pathophysiological marker of treatment-resistant schizophrenia, or a result of antipsychotic exposure, remains to be explored.

Original languageEnglish
Article number109839
JournalProgress in Neuro-Psychopharmacology and Biological Psychiatry
Volume99
DOIs
Publication statusPublished - 2020 Apr 20

Fingerprint

Antipsychotic Agents
Schizophrenia
Globus Pallidus
Corpus Striatum
Clozapine
Therapeutics
Putamen
Chlorpromazine
Brain
Amygdala
Hippocampus
Regression Analysis

Keywords

  • Antipsychotics
  • Clozapine
  • Hippocampus
  • Subcortical
  • Treatment-resistant schizophrenia
  • Volume

ASJC Scopus subject areas

  • Pharmacology
  • Biological Psychiatry

Cite this

Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. / Kim, Julia; Plitman, Eric; Iwata, Yusuke; Nakajima, Shinichiro; Mar, Wanna; Patel, Raihaan; Chavez, Sofia; Chung, Jun Ku; Caravaggio, Fernando; Chakravarty, M. Mallar; Remington, Gary; Gerretsen, Philip; Graff-Guerrero, Ariel.

In: Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 99, 109839, 20.04.2020.

Research output: Contribution to journalArticle

Kim, J, Plitman, E, Iwata, Y, Nakajima, S, Mar, W, Patel, R, Chavez, S, Chung, JK, Caravaggio, F, Chakravarty, MM, Remington, G, Gerretsen, P & Graff-Guerrero, A 2020, 'Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders', Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 99, 109839. https://doi.org/10.1016/j.pnpbp.2019.109839
Kim, Julia ; Plitman, Eric ; Iwata, Yusuke ; Nakajima, Shinichiro ; Mar, Wanna ; Patel, Raihaan ; Chavez, Sofia ; Chung, Jun Ku ; Caravaggio, Fernando ; Chakravarty, M. Mallar ; Remington, Gary ; Gerretsen, Philip ; Graff-Guerrero, Ariel. / Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders. In: Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2020 ; Vol. 99.
@article{1ed9af8209ad4992bac549fcd3ba9821,
title = "Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders",
abstract = "Widespread structrual abnormalities in subcortical brain regions have been identified in patients with schizophrenia. However, only a few studies have examined the neuroanatomical profiles of patients with treatment-resistant schizophrenia. The aim of this study was to compare differences in subcortical and hippocampal volumes between: (i) treatment-resistant patients who are non-responders to both first-line antipsychotics and clozapine (URS), (ii) treatment-resistant patients who are non-responders to first-line antipsychotics but are responders to clozapine (CLZ-Resp), (iii) responders to first-line antipsychotics (FL-Resp), and (iv) healthy controls. T1-weighted images of 103 participants (27 URS, 29 CLZ-Resp, 21 FL-Resp, and 26 healthy controls) were obtained. Group differences in striatal, thalamic, globus pallidus, amygdala, and hippocampus volumes were examined. Multiple regression analyses were performed to examine the associations between subcortical and hippocampal volumes and participant characteristics. The FL-Resp group showed larger striatal and globus pallidus volumes compared to the URS group and larger post-commissural putamen and globus pallidus volumes compared to healthy controls. The URS group showed smaller thalamic volume compared to healthy controls. There were no subcortical or hippocampal volume differences between the URS and CLZ-Resp groups. Differences in subcortical and hippocampal structural volumes were not related to symptom severity or chlorpromazine antipsychotic dose equivalents. Our findings suggest different structural volume alterations in subcortical brain regions between treatment-resistant schizophrenia and responders to first-line antipsychotics. Whether subcortical structure compromise is a distinct pathophysiological marker of treatment-resistant schizophrenia, or a result of antipsychotic exposure, remains to be explored.",
keywords = "Antipsychotics, Clozapine, Hippocampus, Subcortical, Treatment-resistant schizophrenia, Volume",
author = "Julia Kim and Eric Plitman and Yusuke Iwata and Shinichiro Nakajima and Wanna Mar and Raihaan Patel and Sofia Chavez and Chung, {Jun Ku} and Fernando Caravaggio and Chakravarty, {M. Mallar} and Gary Remington and Philip Gerretsen and Ariel Graff-Guerrero",
year = "2020",
month = "4",
day = "20",
doi = "10.1016/j.pnpbp.2019.109839",
language = "English",
volume = "99",
journal = "Progress in Neuro-Psychopharmacology and Biological Psychiatry",
issn = "0278-5846",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Neuroanatomical profiles of treatment-resistance in patients with schizophrenia spectrum disorders

AU - Kim, Julia

AU - Plitman, Eric

AU - Iwata, Yusuke

AU - Nakajima, Shinichiro

AU - Mar, Wanna

AU - Patel, Raihaan

AU - Chavez, Sofia

AU - Chung, Jun Ku

AU - Caravaggio, Fernando

AU - Chakravarty, M. Mallar

AU - Remington, Gary

AU - Gerretsen, Philip

AU - Graff-Guerrero, Ariel

PY - 2020/4/20

Y1 - 2020/4/20

N2 - Widespread structrual abnormalities in subcortical brain regions have been identified in patients with schizophrenia. However, only a few studies have examined the neuroanatomical profiles of patients with treatment-resistant schizophrenia. The aim of this study was to compare differences in subcortical and hippocampal volumes between: (i) treatment-resistant patients who are non-responders to both first-line antipsychotics and clozapine (URS), (ii) treatment-resistant patients who are non-responders to first-line antipsychotics but are responders to clozapine (CLZ-Resp), (iii) responders to first-line antipsychotics (FL-Resp), and (iv) healthy controls. T1-weighted images of 103 participants (27 URS, 29 CLZ-Resp, 21 FL-Resp, and 26 healthy controls) were obtained. Group differences in striatal, thalamic, globus pallidus, amygdala, and hippocampus volumes were examined. Multiple regression analyses were performed to examine the associations between subcortical and hippocampal volumes and participant characteristics. The FL-Resp group showed larger striatal and globus pallidus volumes compared to the URS group and larger post-commissural putamen and globus pallidus volumes compared to healthy controls. The URS group showed smaller thalamic volume compared to healthy controls. There were no subcortical or hippocampal volume differences between the URS and CLZ-Resp groups. Differences in subcortical and hippocampal structural volumes were not related to symptom severity or chlorpromazine antipsychotic dose equivalents. Our findings suggest different structural volume alterations in subcortical brain regions between treatment-resistant schizophrenia and responders to first-line antipsychotics. Whether subcortical structure compromise is a distinct pathophysiological marker of treatment-resistant schizophrenia, or a result of antipsychotic exposure, remains to be explored.

AB - Widespread structrual abnormalities in subcortical brain regions have been identified in patients with schizophrenia. However, only a few studies have examined the neuroanatomical profiles of patients with treatment-resistant schizophrenia. The aim of this study was to compare differences in subcortical and hippocampal volumes between: (i) treatment-resistant patients who are non-responders to both first-line antipsychotics and clozapine (URS), (ii) treatment-resistant patients who are non-responders to first-line antipsychotics but are responders to clozapine (CLZ-Resp), (iii) responders to first-line antipsychotics (FL-Resp), and (iv) healthy controls. T1-weighted images of 103 participants (27 URS, 29 CLZ-Resp, 21 FL-Resp, and 26 healthy controls) were obtained. Group differences in striatal, thalamic, globus pallidus, amygdala, and hippocampus volumes were examined. Multiple regression analyses were performed to examine the associations between subcortical and hippocampal volumes and participant characteristics. The FL-Resp group showed larger striatal and globus pallidus volumes compared to the URS group and larger post-commissural putamen and globus pallidus volumes compared to healthy controls. The URS group showed smaller thalamic volume compared to healthy controls. There were no subcortical or hippocampal volume differences between the URS and CLZ-Resp groups. Differences in subcortical and hippocampal structural volumes were not related to symptom severity or chlorpromazine antipsychotic dose equivalents. Our findings suggest different structural volume alterations in subcortical brain regions between treatment-resistant schizophrenia and responders to first-line antipsychotics. Whether subcortical structure compromise is a distinct pathophysiological marker of treatment-resistant schizophrenia, or a result of antipsychotic exposure, remains to be explored.

KW - Antipsychotics

KW - Clozapine

KW - Hippocampus

KW - Subcortical

KW - Treatment-resistant schizophrenia

KW - Volume

UR - http://www.scopus.com/inward/record.url?scp=85076518277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85076518277&partnerID=8YFLogxK

U2 - 10.1016/j.pnpbp.2019.109839

DO - 10.1016/j.pnpbp.2019.109839

M3 - Article

AN - SCOPUS:85076518277

VL - 99

JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry

JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry

SN - 0278-5846

M1 - 109839

ER -